Pharming Group N.V. (PHAR)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Pharming Group N.V. (“Pharming Group” or “the Company”) (NASDAQ: PHAR). Investors who purchased Pharming Group securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether Pharming Group has violated federal securities laws.
Pharming Group Investigation Details
Pharming Group N.V. reported second-quarter 2026 financial results, including revenue of $90.2 million, a 3% year-over-year decline, and lowered its full-year 2026 revenue guidance to $375 million to $395 million, down from its prior guidance of $405 million to $425 million. The reduction was driven primarily by weaker-than-expected RUCONEST sales, which declined 10% year-over-year to $72.3 million, partially offset by Joenja revenue growth of 40% to $17.9 million. The Company’s revised outlook represented a reduction of approximately $30 million at the midpoint and fell below analyst expectations. The investigation concerns whether Pharming Group adequately disclosed the competitive and demand pressures affecting RUCONEST prior to lowering its full-year guidance. Following this news, Pharming Group’s stock price dropped about 22% on July 30, 2026.
What’s Next for Pharming Group Investors?
If you are aware of any facts relating to this investigation or purchased Pharming Group securities, you can assist this investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Pharming Group Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC For Pharming Group Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
“Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace,” said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | [email protected]
Attorney advertising.
Prior results do not guarantee similar outcomes.